Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth

Cathodic adsorptive stripping square-wave voltammetric determination of nifedipine drug in bulk, pharmaceutical formulation and human serum

“…Several analytical methods have been described for the assay of nifedipine in pharmaceutical formulations and biological fluids. These methods include spectrophotometry [3,4,5,6], gas chromatography [5,6,7,8,9,10,11,12,13,14], liquid chromatography [6,15,16], high-performance thin-layer chromatography [17], high-performance liquid chromatography [18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41], flow-injection tandem mass spectrometry [42] polarography [43,44], linear-sweep voltammetry [45] and differential-pulse stripping voltammetry [46,47].…”

A clinical review of drug‐induced gingival overgrowths

“…It has been reported as the cause of gingival ove r gr owth in three patients and is likely to be a rare condition. 71 A recent small observational study was unable to show an increased prevalence of gi n gi val ove r gr owth in 150 patients taking amlodipine at 5 mg/day for at least six months. 7 2 G i n gi val ove rgrowth began two to three months after starting the m e d i c ation at 5-10 mg/day and the authors felt these changes were compounded by the patients' existing periodontal condition.…”

Amlodipine-Induced Gingival Overgrowth: A Case Report

“…Recently, Lafzi et al (2006) had reported rapidly developed gingival hyperplasia in patient received 10 mg per day of amlodipine within two months of onset. Amlodipine, a dihydropyridine derivative is a third generation of calcium channel blockers which shown to have longer action and weaker side effect compared to the first generation such as nifedipine (Ellis et al, 1993). The prevalence of GO in patients taking amlodipine was reported to be 3.3% (Jorgensen, 1997) which is lower than the rate in patients taking nifedipine, 47.8% (Nery et al, 1995).…”